|
|
|
February 8, 2012 | Illumina CEO Jay Flatley has informed Roche that its unsolicited tender offer of $44.50 per share is "grossly inadequate in multiple respects, dramatically undervalues Illumina and is contrary to the best interests of Illumina's stockholders." BusinessWire
|
|
|